lokelma
astrazeneca ab - natrium zirkonium cyclosilicate - hyperkalemia - kaikki muut terapeuttiset tuotteet - lokelma on tarkoitettu hoitoon hyperkalemia aikuisilla potilailla.
veltassa
vifor fresenius medical care renal pharma france - patiromer sorbitex kalsiumia - hyperkalemia - lääkkeitä hoitoon hyperkalemia ja hyperphosphatemia - veltassa on tarkoitettu hyperkalemiaa aikuisille.
calmia 20 mg lääkepurukumi
meda otc - dimenhydrinatum - lääkepurukumi - 20 mg - difenhydramiini
clomicalm
virbac s.a. - clomipramine hydrochloride - psychoanaleptics - koirat - as an aid in the treatment of separation related disorders in dogs manifested by destruction and inappropriate elimination (defecation and urination) and only in combination with behavioural modification techniques.
sparkal 5 mg / 50 mg tabletti
hexal a/s - hydrochlorothiazidum,amiloridi hydrochloridum dihydricum - tabletti - 5 mg / 50 mg - hydroklooritiatsidi ja kaliumia säästävät diureetit
sparkal mite 2.5 mg / 25 mg tabletti
hexal a/s - hydrochlorothiazidum,amiloridi hydrochloridum dihydricum - tabletti - 2.5 mg / 25 mg - hydroklooritiatsidi ja kaliumia säästävät diureetit
airomir autohaler 0.1 mg/annos inhalaatiosumute, suspensio
teva sweden ab - salbutamol sulfate - inhalaatiosumute, suspensio - 0.1 mg/annos - salbutamoli
kalitabs 750 mg depottabletti
karo pharma ab karo pharma ab - kalii chloridum - depottabletti - 750 mg - kaliumkloridi
kalitabs 1000 mg depottabletti
karo pharma ab karo pharma ab - kalii chloridum - depottabletti - 1000 mg - kaliumkloridi
qaialdo
nova laboratories ireland limited - spironolaktoni - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 ja 5.